Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1350

  • Showing results for sequencing circulating tumor dna. Your search for seqeuncing circulating tumor dna retrieved no results.
1.

Detection of Circulating Tumor DNA with a Single-Molecule Sequencing Analysis Validated for Targeted and Immunotherapy Selection.

Atkins A, Gupta P, Zhang BM, Tsai WS, Lucas J, Javey M, Vora A, Mei R.

Mol Diagn Ther. 2019 Jun 17. doi: 10.1007/s40291-019-00406-0. [Epub ahead of print]

PMID:
31209714
2.

The Role of Circulating Tumor DNA in Lung Cancer: Mutational Analysis, Diagnosis, and Surveillance Now and into the Future.

Scilla KA, Rolfo C.

Curr Treat Options Oncol. 2019 Jun 15;20(7):61. doi: 10.1007/s11864-019-0653-2. Review.

PMID:
31203467
3.

Identification of driver genes and somatic mutations in cell-free DNA of patients with pulmonary lymphangioleiomyomatosis.

Zhang L, Wang MJ, Wang W, Zhao JY, Wu JL, Liu YP, Zhu H, Qu JM, Zhou M.

Int J Cancer. 2019 Jun 14. doi: 10.1002/ijc.32511. [Epub ahead of print]

PMID:
31199508
4.

Temporal and Spatial Effects and Survival Outcomes Associated with Concordance between Tissue and Blood KRAS Alterations in the Pan-Cancer Setting.

Mardinian K, Okamura R, Kato S, Kurzrock R.

Int J Cancer. 2019 Jun 14. doi: 10.1002/ijc.32510. [Epub ahead of print]

PMID:
31199507
5.

Coaxial sensing bio-amplifier for ultrasensitive detections of circulating tumor DNAs.

Zhang Z, Zhu M, Chen Z, Wang X, Chen G, Zhang S.

Biosens Bioelectron. 2019 Jun 5;141:111414. doi: 10.1016/j.bios.2019.111414. [Epub ahead of print]

PMID:
31195204
6.

Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer.

Zhang X, Ju S, Wang X, Cong H.

Clin Exp Med. 2019 Jun 12. doi: 10.1007/s10238-019-00563-w. [Epub ahead of print] Review.

PMID:
31190187
7.

Design of a liver cancer-specific selector for the analysis of circulating tumor DNA.

Sun Y, Meng R, Tang H, Wang H, Guo X, Ma Y, Yang Y, Wei X, Mu F, Wu G, Wang J, Liu J, Niu M, Xue J.

Oncol Lett. 2019 Jun;17(6):5369-5376. doi: 10.3892/ol.2019.10243. Epub 2019 Apr 12.

8.

Transformation to small cell lung cancer and activation of KRAS during long-term erlotinib maintenance in a patient with non-small cell lung cancer: A case report.

Gu Y, Zhu X, Cao B, Wu X, Tong X, Shao YW, Liang L.

Oncol Lett. 2019 Jun;17(6):5219-5223. doi: 10.3892/ol.2019.10196. Epub 2019 Mar 28.

9.

ClonoSEQ assay for the detection of lymphoid malignancies.

Monter A, Nomdedéu JF.

Expert Rev Mol Diagn. 2019 Jun 10:1-8. doi: 10.1080/14737159.2019.1627877. [Epub ahead of print]

PMID:
31179776
10.

Assessment of ctDNA in CSF may be a more rapid means of assessing surgical outcomes than plasma ctDNA in glioblastoma.

Li JH, He ZQ, Lin FH, Chen ZH, Yang SY, Duan H, Jiang XB, Al-Nahari F, Zhang XH, Wang JH, Zhang GH, Zhang ZF, Li C, Mou YG.

Mol Cell Probes. 2019 Jun 4. pii: S0890-8508(19)30132-X. doi: 10.1016/j.mcp.2019.06.001. [Epub ahead of print]

PMID:
31173881
11.

Monitoring of cancer patients via next-generation sequencing of patient-derived circulating tumor cells and tumor DNA.

Onidani K, Shoji H, Kakizaki T, Yoshimoto S, Okaya S, Miura N, Sekikawa S, Furuta K, Lim CT, Shibahara T, Boku N, Kato K, Honda K.

Cancer Sci. 2019 Jun 6. doi: 10.1111/cas.14092. [Epub ahead of print]

12.

Serial Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer to Predict the Therapeutic Response.

Jia N, Sun Z, Gao X, Cheng Y, Zhou Y, Shen C, Chen W, Wang X, Shi R, Li N, Zhou J, Bai C.

Front Genet. 2019 May 21;10:470. doi: 10.3389/fgene.2019.00470. eCollection 2019.

13.

The labyrinth of product development and regulatory approvals in liquid biopsy diagnostics.

Goodsaid FM.

Clin Transl Sci. 2019 Jun 4. doi: 10.1111/cts.12657. [Epub ahead of print] Review.

PMID:
31162800
14.

Safety, Efficacy and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial.

Li Q, Guan X, Chen S, Yi Z, Lan B, Xing P, Fan Y, Wang J, Luo Y, Yuan P, Cai R, Zhang P, Li Q, Zhong D, Zhang Y, Zou JJ, Zhu X, Ma F, Xu B.

Clin Cancer Res. 2019 May 28. pii: clincanres.4173.2018. doi: 10.1158/1078-0432.CCR-18-4173. [Epub ahead of print]

PMID:
31138588
15.

The road map of cancer precision medicine with the innovation of advanced cancer detection technology and personalized immunotherapy.

Low SK, Nakamura Y.

Jpn J Clin Oncol. 2019 May 28. pii: hyz073. doi: 10.1093/jjco/hyz073. [Epub ahead of print]

PMID:
31135897
16.

Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer.

Torquato S, Pallavajjala A, Goldstein A, Toro PV, Silberstein JL, Lee J, Nakazawa M, Waters I, Chu D, Shinn D, Groginski T, Hughes RM, Simons BW, Khan H, Feng Z, Carducci MA, Paller CJ, Denmeade SR, Kressel B, Eisenberger MA, Antonarakis ES, Trock BJ, Park BH, Hurley PJ.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00227. Epub 2019 Apr 3.

17.

Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells.

Garcia J, Wozny AS, Geiguer F, Delherme A, Barthelemy D, Merle P, Tissot C, Jones FS, Johnson C, Xing X, Xu Z, Edelstein DL, Brevet M, Souquet PJ, Rodriguez-Lafrasse C, Payen L, Couraud S.

Cancer Med. 2019 May 21. doi: 10.1002/cam4.2244. [Epub ahead of print]

18.

TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma.

Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leshchiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, Reyes S, Sagara T, Otsuki S, Nadres B, Shahzade HA, Dey-Guha I, Fetter IJ, Baiev I, Van Seventer EE, Murphy JE, Ferrone CR, Tanabe KK, Deshpande V, Harding JJ, Yaeger R, Kelley RK, Bardelli A, Iafrate AJ, Hahn WC, Benes CH, Ting DT, Hirai H, Getz G, Juric D, Zhu AX, Corcoran RB, Bardeesy N.

Cancer Discov. 2019 May 20. pii: CD-19-0182. doi: 10.1158/2159-8290.CD-19-0182. [Epub ahead of print]

PMID:
31109923
19.

Progress and challenges in HER2-positive gastroesophageal adenocarcinoma.

Zhao D, Klempner SJ, Chao J.

J Hematol Oncol. 2019 May 17;12(1):50. doi: 10.1186/s13045-019-0737-2. Review.

20.

Liquid Biopsy: General Concepts.

Poulet G, Massias J, Taly V.

Acta Cytol. 2019 May 15:1-7. doi: 10.1159/000499337. [Epub ahead of print] Review.

PMID:
31091522

Supplemental Content

Loading ...
Support Center